These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24552880)

  • 1. Abuse liability of centrally acting non-opioid analgesics and muscle relaxants--a brief update based on a comparison of pharmacovigilance data and evidence from the literature.
    Gahr M; Freudenmann RW; Eller J; Schönfeldt-Lecuona C
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):957-9. PubMed ID: 24552880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse liability of flupirtine revisited: implications of spontaneous reports of adverse drug reactions.
    Gahr M; Freudenmann RW; Connemann BJ; Hiemke C; Schönfeldt-Lecuona C
    J Clin Pharmacol; 2013 Dec; 53(12):1328-33. PubMed ID: 24037995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database.
    Carnovale C; Mahzar F; Scibelli S; Gentili M; Arzenton E; Moretti U; Leoni O; Pozzi M; Peeters GGAM; Clementi E; Medaglia M; Radice S
    Eur J Pediatr; 2019 Feb; 178(2):161-172. PubMed ID: 30374752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Centrally acting muscle relaxants and traffic hazards].
    Bramness JG; Skurtveit S; Grung M; Mørland J
    Tidsskr Nor Laegeforen; 2000 Jun; 120(17):1966-9. PubMed ID: 11008526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse potential of carisoprodol: a retrospective review of Idaho Medicaid pharmacy and medical claims data.
    Owens C; Pugmire B; Salness T; Culbertson V; Force R; Cady P; Steiner J
    Clin Ther; 2007 Oct; 29(10):2222-5. PubMed ID: 18042478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for physical and behavioral dependence on non-opioid analgesics in a German elderly hospital population.
    Bonnet U; Strasser JC; Scherbaum N
    Addict Behav; 2019 Mar; 90():265-271. PubMed ID: 30472534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregabalin abuse and dependence in Germany: results from a database query.
    Gahr M; Freudenmann RW; Hiemke C; Kölle MA; Schönfeldt-Lecuona C
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1335-42. PubMed ID: 23292158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose tizanidine abuse.
    Zullino DF; Eskenasy AC; Beeson J
    Psychopharmacol Bull; 2003; 37(3):5-6. PubMed ID: 15270008
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenprobamate dependence: a case report.
    Demir B; Demir Y; Aksoy I; Kilic OH; Gucyetmez V; Savas HA
    Addict Behav; 2015 Jun; 45():232-3. PubMed ID: 25727392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical therapy for radiculopathy.
    Visco CJ; Cheng DS; Kennedy DJ
    Phys Med Rehabil Clin N Am; 2011 Feb; 22(1):127-37. PubMed ID: 21292149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance databases.
    Gahr M; Zeiss R; Lang D; Connemann BJ; Hiemke C; Freudenmann RW; Schönfeldt-Lecuona C
    Pharmacopsychiatry; 2015 Jan; 48(1):19-24. PubMed ID: 25376976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carisoprodol: update on abuse potential and legal status.
    Reeves RR; Burke RS; Kose S
    South Med J; 2012 Nov; 105(11):619-23. PubMed ID: 23128807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carisoprodol legal status and patterns of abuse.
    Fass JA
    Ann Pharmacother; 2010 Dec; 44(12):1962-7. PubMed ID: 21062909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Centrally acting oral skeletal muscle relaxants.
    Elenbaas JK
    Am J Hosp Pharm; 1980 Oct; 37(10):1313-23. PubMed ID: 6999895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.
    Schifano F; Chiappini S
    PLoS One; 2018; 13(10):e0204443. PubMed ID: 30286103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the market withdrawal of carisoprodol on use of other prescribed drugs with abuse potential.
    Bramness JG; Furu K; Skurtveit S; Engeland A
    Clin Pharmacol Ther; 2012 Mar; 91(3):438-41. PubMed ID: 22318620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carisoprodol abuse in Mississippi.
    Reeves RR; Henderson RH; Ladner ME
    J Miss State Med Assoc; 2007 Dec; 48(12):363-5. PubMed ID: 19292137
    [No Abstract]   [Full Text] [Related]  

  • 18. Abuse of skeletal muscle relaxants.
    Elder NC
    Am Fam Physician; 1991 Oct; 44(4):1223-6. PubMed ID: 1927837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carisoprodol: an underrecognized drug of abuse in north India.
    Nebhinani N; Aggarwal M; Mattoo SK; Basu D
    Gen Hosp Psychiatry; 2013; 35(1):89-92. PubMed ID: 22959419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the clinical evidence leading to tetrazepam withdrawal.
    Proy-Vega B; Aguirre C; de Groot P; Solís-García del Pozo J; Jordán J
    Expert Opin Drug Saf; 2014 Jun; 13(6):705-12. PubMed ID: 24845943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.